A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)
A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)
This study will assess the bioequivalence in healthy participants between a
 high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a
 single injection by a needle and syringe, and a low-concentration formulation of lebrikizumab
 administered SC as a single injection via PFS-NSD.
Inclusion Criteria:

 -  Healthy adults 18 to 65 years of age, inclusive

 -  Body mass index (BMI) 18 to 32 kg/m^2 and body weight 50 to 100 kg, inclusive

 -  Nonpregnant and nonlactating females

 -  Agreement to utilize effective contraception among men and women of childbearing
 potential

 Exclusion Criteria:

 -  Known allergy or hypersensitivity to study drug or components

 -  History of alcohol or drug abuse within 12 months prior to study drug, or positive
 test for alcohol or drugs of abuse

 -  Receipt of an investigational agent within 30 days of 5 half-lives prior to Day -1

 -  Biological therapy within 90 days prior to Day -1

 -  Parasitic or Listeria monocytogenes infection within 6 months prior to Screening

 -  Receipt of blood products within 2 months prior to study entry

 -  Donation or loss of blood/plasma within up to 6 months prior to study drug, depending
 upon volume

 -  Receipt of live attenuated vaccine within 1 month prior to study drug

 -  Use of tobacco- or nicotine-containing products within 14 days prior to Screening

 -  Use of any prescription or nonprescription medication within 14 days prior to study
 drug